Radiopharm Theranostics Raises US$13M via Offerings & Share Plan
Radiopharm Theranostics Ltd announced a multi-faceted capital raise totaling approximately US$13.0 million. This includes a US$4.1 million registered direct offering of American Depositary Shares (ADSs) and a concurrent private placement of warrants. Additionally, the company secured A$6.7 million (US$4.7 million) from an Australian Placement and plans a Share Purchase Plan to raise up to A$6 million (US$4.2 million) for existing shareholders. A significant portion of the Australian capital raise and associated options will require shareholder approval at an extraordinary general meeting scheduled for September 11, 2026. The funds are intended to advance the RAD101 registrational study, progress therapeutic programs, and for general corporate purposes.
Key Highlights
- Radiopharm Theranostics announced a US$4.1 million registered direct offering of 1,281,646 ADSs at US$3.16 per ADS.
- Concurrent private placement of warrants to purchase up to 1,281,646 ADSs at US$3.79 per ADS, expiring July 31, 2029.
- Australian Placement secured A$6.7 million (US$4.7 million) from institutional and professional investors.
- Share Purchase Plan to raise up to an additional A$6 million (US$4.2 million) for Australian and New Zealand shareholders.
- Total capital raise from all offerings is approximately US$13.0 million.
- Shareholder approval required for certain parts of the Australian Placement, Share Purchase Plan, and options.
- Funds will support the RAD101 registrational study, therapeutic programs, and general corporate purposes.
- Extraordinary general meeting for shareholder approvals is expected on or about September 11, 2026.
Price Impact
More from RADX